Review: Transcranial Direct Current Stimulation Eases Migraine

FRIDAY, April 29, 2022 (HealthDay News) -- Transcranial direct current stimulation (tDCS) is effective and safe for migraine, according to a review published online April 19 in CNS Neuroscience and Therapeutics.
Peiwei Hong, from Sichuan University in Chengdu, China, and colleagues conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to examine the efficacy and safety of tDCS for migraine. The meta-analysis included 11 RCTs with 425 patients with migraine. The RCTs examined the efficacy and safety of anodal or cathodal stimulation targeting different brain areas, including the primary motor cortex (M1), primary sensory cortex (S1), dorsolateral prefrontal cortex (DLPFC), and visual cortex (VC).
The researchers found that in patients with migraine, the number of migraine days per month was reduced with tDCS with M1 and VC activation. Migraine pain intensity could be improved with tDCS with activation of DLPFC and M1. tDCS with VC inhibition could also reduce the number of migraine days per month. Pain intensity could be reduced with tDCS with inhibition of M1, S1, and VC. No difference in the incidences of adverse events was seen between the active stimulation and sham stimulation groups.
"Our results showed that either activating or inhibiting M1 or VC could improve migraine prognosis," the authors write. "Meanwhile, activating the DLPFC or inhibiting S1 could improve migraine prognosis."
Related Posts
Estrogen May Help Fight Severe COVID-19
WEDNESDAY, May 18, 2022 (HealthDay News) -- Hormone replacement therapy may...
1.3 Billion People Worldwide Could Have Diabetes by 2050
FRIDAY, June 23, 2023 (HealthDay News) -- Diabetes is skyrocketing, with more...
Concussion Linked to Mental Health Issues Among Children Aged 5 to 18 Years
WEDNESDAY, March 9, 2022 (HealthDay News) -- For children aged 5 to 18 years,...
Nueve de cada 10 estadounidenses quieren que su información de salud se mantenga privada
MARTES, 2 de agosto de 2022 (HealthDay News) -- Más de 9 de cada 10...
